Database Query Results : , , cMET

cMET, cellular hepatocyte growth factor receptor: Click to Expand ⟱
Source:
Type:
c-MET, also known as the hepatocyte growth factor receptor (HGFR), is a receptor tyrosine kinase that plays a crucial role in various cellular processes, including cell proliferation, survival, migration, and differentiation. It is activated by its ligand, hepatocyte growth factor (HGF). Dysregulation of the c-MET signaling pathway has been implicated in several types of cancer.

c-Met is often overexpressed or mutated in cancer and is associated with poor prognosis, increased metastasis, and resistance to therapies.
Scientific Papers found: Click to Expand⟱
308- Api,    Apigenin Inhibits Cancer Stem Cell-Like Phenotypes in Human Glioblastoma Cells via Suppression of c-Met Signaling
- in-vitro, GBM, U87MG - in-vitro, GBM, U373MG
cMET↓, Akt↓, Nanog↓, SOX2↓,
556- ART/DHA,    Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing
- Review, NA, NA
IL6↓, IL1↓, TNF-α↓, TGF-β↓, NF-kB↓, MIP2↓, PGE2↓, NO↓, Hif1a↓, KDR/FLK-1↓, VEGF↓, MMP2↓, TIMP2↑, ITGB1↑, NCAM↑, p‑ATM↑, p‑ATR↑, p‑CHK1↑, p‑Chk2↑, Wnt/(β-catenin)↓, PI3K↓, Akt↓, ERK↓, cMyc↓, mTOR↓, survivin↓, cMET↓, EGFR↓, cycD1/CCND1↓, cycE1↓, CDK4/6↓, p16↑, p27↑, Apoptosis↑, TumAuto↑, Ferroptosis↑, oncosis↑, TumCCA↑, ROS↑, DNAdam↑, RAD51↓, HR↓,
3156- Ash,    Withaferin A: From ayurvedic folk medicine to preclinical anti-cancer drug
- Review, Var, NA
MAPK↑, p38↑, BAX↑, BIM↑, CHOP↑, ROS↑, DR5↑, Apoptosis↑, Ferroptosis↑, GPx4↓, BioAv↝, HSP90↓, RET↓, E6↓, E7↓, Akt↓, cMET↓, Glycolysis↓, TCA↓, NOTCH1↓, STAT3↓, AP-1↓, PI3K↓, eIF2α↓, HO-1↑, TumCCA↑, CDK1↓, *hepatoP↑, *GSH↑, *NRF2↑, Wnt↓, EMT↓, uPA↓, CSCs↓, Nanog↓, SOX2↓, CD44↓, lactateProd↓, Iron↑, NF-kB↓,
473- CUR,    Curcumin inhibits epithelial-mesenchymal transition in oral cancer cells via c-Met blockade
- in-vitro, Oral, HSC4 - in-vitro, Oral, Ca9-22
Vim↓, p‑cMET↓, p‑ERK↓, pro‑MMP9↓, E-cadherin↑,
1443- Deg,    Deguelin Action Involves c-Met and EGFR Signaling Pathways in Triple Negative Breast Cancer Cells
- vitro+vivo, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-435 - in-vitro, BC, BT549
EGFR↓, Akt↓, p‑ERK↓, NF-kB↓, p‑STAT3↓, survivin↓, Myc↓, TumCG↓, cMET↓,
1446- Deg,    Efficacy and mechanism of action of Deguelin in suppressing metastasis of 4T1 cells
- in-vitro, BC, 4T1
cMET↓, p‑ERK↓, p‑Akt↓, TumCMig↓, TumCG↓, Weight∅, *toxicity∅, Hif1a↓, TumMeta↓,
2868- HNK,    Honokiol: A review of its pharmacological potential and therapeutic insights
- Review, Var, NA - Review, Sepsis, NA
*P-gp↓, *ROS↓, *TNF-α↓, *IL10↓, *IL6↓, eIF2α↑, CHOP↑, GRP78/BiP↑, BAX↑, cl‑Casp9↑, p‑PERK↑, ER Stress↑, Apoptosis↑, MMPs↓, cFLIP↓, CXCR4↓, Twist↓, HDAC↓, BMPs↑, p‑STAT3↓, mTOR↓, EGFR↓, NF-kB↓, Shh↓, VEGF↓, tumCV↓, TumCMig↓, TumCI↓, ERK↓, Akt↓, Bcl-2↓, Nestin↓, CD133↓, p‑cMET↑, RAS↑, chemoP↑, *NRF2↑, *NADPH↓, *p‑Rac1↓, *ROS↓, *IKKα↑, *NF-kB↓, *COX2↓, *PGE2↓, *Casp3↓, *hepatoP↑, *antiOx↑, *GSH↑, *Catalase↑, *RenoP↑, *ALP↓, *AST↓, *ALAT↓, *neuroP↑, *cardioP↑, *HO-1↑, *Inflam↓,
1200- LT,    Inhibition of Fatty Acid Synthase by Luteolin Post-Transcriptionally Downregulates c-Met Expression Independent of Proteosomal/Lysosomal Degradation
- in-vitro, Pca, DU145
FASN↓, cMET↓, HGF/c-Met↓,
4646- OLEC,    Oleocanthal as a Multifunctional Anti-Cancer Agent: Mechanistic Insights, Advanced Delivery Strategies, and Synergies for Precision Oncology
- Review, Var, NA
BioAv↓, *Inflam↓, *antiOx↓, cMET↓, STAT3↓, TNF-α↓, COX2↓, EMT↓, angioG↓, *GutMicro↝, eff↑,
2948- PL,    The promising potential of piperlongumine as an emerging therapeutics for cancer
- Review, Var, NA
tumCV↓, TumCP↓, TumCI↓, angioG↓, EMT↓, TumMeta↓, *hepatoP↑, *lipid-P↓, *GSH↑, cardioP↑, CycB/CCNB1↓, cycD1/CCND1↓, CDK2↓, CDK1↓, CDK4↓, CDK6↓, PCNA↓, Akt↓, mTOR↓, Glycolysis↓, NF-kB↓, IKKα↓, JAK1↓, JAK2↓, STAT3↓, ERK↓, cFos↓, Slug↓, E-cadherin↑, TOP2↓, P53↑, P21↑, Bcl-2↓, BAX↑, Casp3↑, Casp7↑, Casp8↑, p‑HER2/EBBR2↓, HO-1↑, NRF2↑, BIM↑, p‑FOXO3↓, Sp1/3/4↓, cMyc↓, EGFR↓, survivin↓, cMET↓, NQO1↑, SOD2↑, TrxR↓, MDM2↓, p‑eIF2α↑, ATF4↑, CHOP↑, MDA↑, Ki-67↓, MMP9↓, Twist↓, SOX2↓, Nanog↓, OCT4↓, N-cadherin↓, Vim↓, Snail↓, TumW↓, TumCG↓, HK2↓, RB1↓, IL6↓, IL8↓, SOD1↑, RadioS↑, ChemoSen↑, toxicity↓, Sp1/3/4↓, GSH↓, SOD↑,
2940- PL,    Piperlongumine Induces Reactive Oxygen Species (ROS)-dependent Downregulation of Specificity Protein Transcription Factors
- in-vitro, PC, PANC1 - in-vitro, Lung, A549 - in-vitro, Kidney, 786-O - in-vitro, BC, SkBr3
ROS↑, TumCP↓, Apoptosis↑, eff↓, Sp1/3/4↓, cycD1/CCND1↓, survivin↓, cMyc↓, EGFR↓, cMET↓,
2995- PL,    Piperlongumine overcomes osimertinib resistance via governing ubiquitination-modulated Sp1 turnover
- in-vitro, Lung, H1975 - in-vitro, Lung, PC9 - in-vivo, NA, NA
Sp1/3/4↓, cMET↓, Apoptosis↑, Cyt‑c↑, p‑ERK↓, p‑Akt↓, TumCG↓,
89- QC,  doxoR,    Quercetin reverses the doxorubicin resistance of prostate cancer cells by downregulating the expression of c-met
- in-vitro, Pca, PC3
PI3K/Akt↓, cMET↓, Casp3↑, Casp9↑, MMP↓,
3427- TQ,    Chemopreventive and Anticancer Effects of Thymoquinone: Cellular and Molecular Targets
ROS⇅, Fas↑, DR5↑, TRAIL↑, Casp3↑, Casp8↑, Casp9↑, P53↑, mTOR↓, Bcl-2↓, BID↓, CXCR4↓, JNK↑, p38↑, MAPK↑, LC3II↑, ATG7↑, Beclin-1↑, AMPK↑, PPARγ↑, eIF2α↓, P70S6K↓, VEGF↓, ERK↓, NF-kB↓, XIAP↓, survivin↓, p65↓, DLC1↑, FOXO↑, TET2↑, CYP1B1↑, UHRF1↓, DNMT1↓, HDAC1↓, IL2↑, IL1↓, IL6↓, IL10↓, IL12↓, TNF-α↓, iNOS↓, COX2↓, 5LO↓, AP-1↓, PI3K↓, Akt↓, cMET↓, VEGFR2↓, CXCL1↓, ITGA5↓, Wnt↓, β-catenin/ZEB1↓, GSK‐3β↓, Myc↓, cycD1/CCND1↓, N-cadherin↓, Snail↓, Slug↓, Vim↓, Twist↓, Zeb1↓, MMP2↓, MMP7↓, MMP9↓, JAK2↓, STAT3↓, NOTCH↓, cycA1/CCNA1↓, CDK2↓, CDK4↓, CDK6↓, CDC2↓, CDC25↓, Mcl-1↓, E2Fs↓, p16↑, p27↑, P21↑, ChemoSen↑,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 14

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Ferroptosis↑, 2,   GPx4↓, 1,   GSH↓, 1,   HO-1↑, 2,   Iron↑, 1,   MDA↑, 1,   NQO1↑, 1,   NRF2↑, 1,   ROS↑, 3,   ROS⇅, 1,   SOD↑, 1,   SOD1↑, 1,   SOD2↑, 1,   TrxR↓, 1,  

Mitochondria & Bioenergetics ⓘ

CDC2↓, 1,   CDC25↓, 1,   MMP↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   ATG7↑, 1,   cMyc↓, 3,   FASN↓, 1,   Glycolysis↓, 2,   HK2↓, 1,   lactateProd↓, 1,   PI3K/Akt↓, 1,   PPARγ↑, 1,   TCA↓, 1,  

Cell Death ⓘ

Akt↓, 7,   p‑Akt↓, 2,   Apoptosis↑, 5,   BAX↑, 3,   Bcl-2↓, 3,   BID↓, 1,   BIM↑, 2,   Casp3↑, 3,   Casp7↑, 1,   Casp8↑, 2,   Casp9↑, 2,   cl‑Casp9↑, 1,   cFLIP↓, 1,   p‑Chk2↑, 1,   Cyt‑c↑, 1,   DR5↑, 2,   Fas↑, 1,   Ferroptosis↑, 2,   HGF/c-Met↓, 1,   iNOS↓, 1,   JNK↑, 1,   MAPK↑, 2,   Mcl-1↓, 1,   MDM2↓, 1,   Myc↓, 2,   oncosis↑, 1,   p27↑, 2,   p38↑, 2,   survivin↓, 5,   TRAIL↑, 1,  

Kinase & Signal Transduction ⓘ

p‑HER2/EBBR2↓, 1,   RET↓, 1,   Sp1/3/4↓, 4,  

Transcription & Epigenetics ⓘ

tumCV↓, 2,  

Protein Folding & ER Stress ⓘ

CHOP↑, 3,   eIF2α↓, 2,   eIF2α↑, 1,   p‑eIF2α↑, 1,   ER Stress↑, 1,   GRP78/BiP↑, 1,   HSP90↓, 1,   p‑PERK↑, 1,  

Autophagy & Lysosomes ⓘ

Beclin-1↑, 1,   LC3II↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair ⓘ

p‑ATM↑, 1,   p‑ATR↑, 1,   p‑CHK1↑, 1,   CYP1B1↑, 1,   DNAdam↑, 1,   DNMT1↓, 1,   HR↓, 1,   p16↑, 2,   P53↑, 2,   PCNA↓, 1,   RAD51↓, 1,   UHRF1↓, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 2,   CDK2↓, 2,   CDK4↓, 2,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 4,   cycE1↓, 1,   E2Fs↓, 1,   P21↑, 2,   RB1↓, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

CD133↓, 1,   CD44↓, 1,   cFos↓, 1,   cMET↓, 12,   p‑cMET↓, 1,   p‑cMET↑, 1,   CSCs↓, 1,   EMT↓, 3,   ERK↓, 4,   p‑ERK↓, 4,   FOXO↑, 1,   p‑FOXO3↓, 1,   GSK‐3β↓, 1,   HDAC↓, 1,   HDAC1↓, 1,   mTOR↓, 4,   Nanog↓, 3,   Nestin↓, 1,   NOTCH↓, 1,   NOTCH1↓, 1,   OCT4↓, 1,   P70S6K↓, 1,   PI3K↓, 3,   RAS↑, 1,   Shh↓, 1,   SOX2↓, 3,   STAT3↓, 4,   p‑STAT3↓, 2,   TOP2↓, 1,   TumCG↓, 4,   Wnt↓, 2,   Wnt/(β-catenin)↓, 1,  

Migration ⓘ

5LO↓, 1,   AP-1↓, 2,   CDK4/6↓, 1,   DLC1↑, 1,   E-cadherin↑, 2,   ITGA5↓, 1,   ITGB1↑, 1,   Ki-67↓, 1,   MMP2↓, 2,   MMP7↓, 1,   MMP9↓, 2,   pro‑MMP9↓, 1,   MMPs↓, 1,   N-cadherin↓, 2,   NCAM↑, 1,   Slug↓, 2,   Snail↓, 2,   TGF-β↓, 1,   TIMP2↑, 1,   TumCI↓, 2,   TumCMig↓, 2,   TumCP↓, 2,   TumMeta↓, 2,   Twist↓, 3,   uPA↓, 1,   Vim↓, 3,   Zeb1↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 2,   ATF4↑, 1,   EGFR↓, 5,   Hif1a↓, 2,   KDR/FLK-1↓, 1,   NO↓, 1,   VEGF↓, 3,   VEGFR2↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   CXCL1↓, 1,   CXCR4↓, 2,   IKKα↓, 1,   IL1↓, 2,   IL10↓, 1,   IL12↓, 1,   IL2↑, 1,   IL6↓, 3,   IL8↓, 1,   JAK1↓, 1,   JAK2↓, 2,   MIP2↓, 1,   NF-kB↓, 6,   p65↓, 1,   PGE2↓, 1,   TNF-α↓, 3,  

Hormonal & Nuclear Receptors ⓘ

CDK6↓, 2,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   BioAv↝, 1,   ChemoSen↑, 2,   eff↓, 1,   eff↑, 1,   RadioS↑, 1,   TET2↑, 1,  

Clinical Biomarkers ⓘ

BMPs↑, 1,   E6↓, 1,   E7↓, 1,   EGFR↓, 5,   p‑HER2/EBBR2↓, 1,   IL6↓, 3,   Ki-67↓, 1,   Myc↓, 2,  

Functional Outcomes ⓘ

cardioP↑, 1,   chemoP↑, 1,   toxicity↓, 1,   TumW↓, 1,   Weight∅, 1,  
Total Targets: 202

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 1,   Catalase↑, 1,   GSH↑, 3,   HO-1↑, 1,   lipid-P↓, 1,   NRF2↑, 2,   ROS↓, 2,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 1,   NADPH↓, 1,  

Cell Death ⓘ

Casp3↓, 1,  

Migration ⓘ

p‑Rac1↓, 1,  

Barriers & Transport ⓘ

P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IKKα↑, 1,   IL10↓, 1,   IL6↓, 1,   Inflam↓, 2,   NF-kB↓, 1,   PGE2↓, 1,   TNF-α↓, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   ALP↓, 1,   AST↓, 1,   GutMicro↝, 1,   IL6↓, 1,  

Functional Outcomes ⓘ

cardioP↑, 1,   hepatoP↑, 3,   neuroP↑, 1,   RenoP↑, 1,   toxicity∅, 1,  
Total Targets: 31

Scientific Paper Hit Count for: cMET, cellular hepatocyte growth factor receptor
3 Piperlongumine
2 Deguelin
1 Apigenin (mainly Parsley)
1 Artemisinin
1 Ashwagandha(Withaferin A)
1 Curcumin
1 Honokiol
1 Luteolin
1 Oleocanthal
1 Quercetin
1 doxorubicin
1 Thymoquinone
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:484  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page